International Flavors to Report Q2 Earnings: Here's What to Expect

International Flavors & Fragrances (IFF) is poised to report Q2 2025 results on August 5, with consensus estimates projecting a 5.4% year-over-year sales dip to $2.73 billion and a 4.3% earnings decline to $1.11 per share. While volume growth and ongoing cost-cutting initiatives are expected to support margins, high raw material and operational costs are anticipated to temper profitability. Despite IFF's history of beating earnings estimates in three of the last four quarters, the Zacks model does not predict a beat this quarter due to a negative Earnings ESP. Segmentally, Health & Biosciences and Taste are forecast for strong sales growth, yet overall sales are expected to decline, contributing to the stock's significant 26.7% underperformance over the past year.

Analysis

International Flavors & Fragrances (IFF) faces a challenging outlook for its second-quarter 2025 earnings, with consensus estimates pointing to a 5.4% year-over-year revenue decline to $2.73 billion and a 4.3% drop in earnings per share to $1.11. This expected contraction occurs despite a history of earnings beats and a minor 0.9% upward revision in profit estimates over the past 60 days. The core issue remains significant margin pressure from elevated raw material, labor, and shipping costs, which are anticipated to negate the benefits of volume growth and cost-reduction initiatives. A deeper look at segment projections reveals a concerning trend: while the Health & Biosciences and Taste segments are forecast to deliver strong sales growth of 21.3% and 8.8% respectively, their adjusted operating EBITDA is expected to grow by a meager 1.0% and 1.5%. This disconnect is even more pronounced in the Scent segment, where a 7.6% sales increase is projected alongside a 5.9% decrease in operating EBITDA. These figures suggest IFF lacks the pricing power or cost control to translate demand into profitability. This fundamental weakness is compounded by quantitative indicators, such as the Zacks model's negative Earnings ESP of -0.31%, which predicts an earnings miss, and the stock's severe underperformance, having lost 26.7% in the past year while its industry declined only 3.3%.

Key Decisions for Investors

• Investors should exercise caution, as the combination of declining headline revenue, significant margin compression from input costs, and a negative quantitative earnings signal from the Zacks model suggests a high probability of negative catalysts from the upcoming report.
• The key metrics to scrutinize will be segment-level operating EBITDA margins, particularly in the high-growth Health & Biosciences and Scent divisions, to assess if management's pricing actions and productivity efforts are beginning to offset cost inflation.
• Given the stock's substantial 26.7% underperformance over the past year, much of the negative news may already be priced in, but initiating or adding to long positions ahead of the report carries notable risk until there is clear evidence of a turnaround in profitability.